Parallel: 2×12, Xover: 12 [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-06-14 20:43 (473 d 22:55 ago) – Posting: # 20327
Views: 1,167

Hi Olivbood,

» The guideline specifies that "At a minimum, 12 subjects should be enrolled in each treatment arm." I deduce from it that this is the minimal sample size considering a parallel design study.

Correct.

» Alternatively, for a classic 2x2 cross-over study the minimal sample size should be 12 subjects in total since each subject will experience both fed and fasted status.
»
» Is my understanding correct?

Correct, again.

I both cases I would include a bit more subjects to be protected against eventual dropouts. I guess the FDA wouldn’t be amused to get a study in 11 subjects although the guidance clearly states “12 enrolled”.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,090 posts in 4,398 threads, 1,469 registered users;
online 22 (2 registered, 20 guests [including 5 identified bots]).
Forum time: Wednesday 19:39 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5